TAGOVAMERAN EXPRESSED SARS-COV-2 SPIKE GLYCOPROTEIN ANTIGEN
UNII 37WJ4R2YAU

Substance Identification & Data

This profile provides standardized clinical and technical data for Tagovameran Expressed Sars-cov-2 Spike Glycoprotein Antigen, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 37WJ4R2YAU.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
37WJ4R2YAU
CAS Registry Number
N/A
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
TAGOVAMERAN EXPRESSED SARS-COV-2 SPIKE GLYCOPROTEIN ANTIGEN
Official standardized name for this substance within the FDA UNII nomenclature system.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tagovameran Expressed Sars-cov-2 Spike Glycoprotein Antigen. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

Common Names & Synonyms

TAGOVAMERAN EXPRESSED SARS-COV-2 SPIKE GLYCOPROTEIN ANTIGEN
TAGOVAMERAN EXPRESSED SARS-COV-2 SPIKE GLYCOPROTEIN, S1 AND S2 DOMAINS, WITH PREFUSION-STABILIZING MUTATIONS (K981P AND V982P), FURIN-CLEAVAGE-INACTIVATING MUTATIONS (R677G, R678S, AND R680S), AND MUTATIONS PRESENT IN THE SPIKE GLYCOPROTEINS OF THE OMICRON BA.4/5 VARIANTS, FOR WHICH THE PROTEIN SEQUENCES ARE IDENTICAL

External Clinical & Regulatory Resources

NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record